https://t.co/R1xWdpwAvQ

Excited to share a publication years in the making, our experience with CAR20.19 T cells in relapsed, refractory Mantle Cell Lymphoma now a. Excellent outcomes from IIT @MCWCancerCenter Thanks to great collaborators @timfenske @MediHumdani and many more! https://t.co/aSLSENN27I

Dr. Fenske @timfenske presenting this important late breaking abstract @niravshahmd @MediHumdani @MCWCancerCenter @ASH_hematology #ASH2024

NX-5948 update in CLL - awesome that they permitted CNS involvement (8%). Tox profile looks good. Enrolled variety of BTK mutants. High ORR and responses may deepen.

A rapidly delivered tandem CAR T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to data at #ASH24. Healio spoke with @niravshahmd of @MedicalCollege about the data. #Lymphoma https://t.co/dx62UnE1wz

CONGRESS | #ASH24 | PRESENTATION Nirav Shah @niravshahmd @mcw_oncology presents interim results from the phase II DALY II USA study. Zamto-cel demonstrated encouraging efficacy, with an ORR of 72.8%, and there were low incidences of CRS and ICANS in patients with R/R DLBCL.

CD19.20 dual CAR in third or later line DLBCL being presented by @niravshahmd #ASH24

Now two multicenter studies with this construct in Europe (2nd line DLBCL) and US (3rd line DLBCL). Thanks to all the people who helped along the way @MCWCancerCenter @MediHumdani @timfenske @Phari among others. Hope to one day see this product approved for pts across the world!

https://t.co/Jz6CAmGNGc Excited to share CAR20.19 multicenter data--a nearly 10 year effort. Developed a Phase 1 trial with this construct in 2016, first patient treated at MCW in 2017. Published Phase 1 with target dose, fresh-in/fresh-out CAR cells in Nature Med in 2020.

In Saturday's #WordOnMedicine podcast, #MCW's @niravshahmd shares how #cancer investigators recently treated the 100th patient in an ongoing #ClinicalTrial using an in-house manufactured, dual-targeted CAR-T therapy for patients with B-cell malignancies: https://t.co/jvYABJAcct

⁦@niravshahmd⁩ presenting our point of care CD19/20 MCL cohort data. N=17. ORR 100%, 88% CR. Only 2 relapses so far. 12% Gr 3 ICANS. No Gr 3-4 CRS. Proud to be part of this work!

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR @mshadman Reminds you to keep an open mind, one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma @niravshahmd @MedicalCollege @ASH_hematology #ASH23 #oncology

There is no worse thing MDs have to do than a peer to peer for drug approval. Endless time wasted

Amazing, and entertaining, session on Aggressive Lymphomas with @sairah__ahmed (@MDAndersonNews), @niravshahmd (@MedicalCollege), and @DholariaMD & @OlaOluwole4 of @VUMChealth here at #HemeSummit23! Great to see lots of audience participation.

👉👉First time in Nashville for the Binaytara Foundation Hem Summit ! @binayshah @FadiHaddad_MD @doctorpemm @TapKadia @sairah__ahmed @BldCancerDoc @SoniSmithMD @myelomaMD @LNastoupilMD @AlexBataller @sanamloghavi @KMirza @Anand_88_Patel @LoriMuffly @niravshahmd

Excited to be a co-author on my first (hopefully not last) paper in NEJM evaluating outcomes of Pirtobrutinib in CLL after prior covalent BTKi. Data speak for themselves and will be a new option for patients with R/R CLL!

NOW PUBLISHED in @JCO_ASCO: Updated results from the phase I/II BRUIN study, investigating a highly selective, non-covalent (reversible) BTKi in patients w/ covalent BTKi pre-treated #MantleCellLymphoma. #lymsm Read the results here: https://t.co/crFIWCwvId

🎥 @niravshahmd of @MedicalCollege discusses the rationale and interim results of a study evaluating split-dose R-CHOP for older patients with advanced-stage #DLBCL👇: https://t.co/Ag1kRu84rk @ASCO #LymSM #HemOnc #ImmunoOnc